Nikkei Industry Sector
Pharmaceuticals
Overview
Japan's pharmaceutical sector includes both large domestic-focused drug makers and globally operating biopharmaceutical companies with significant international revenue. The industry combines deep scientific capability with strong regulatory relationships and a large aging domestic patient population that drives consistent baseline demand.
Current Trend
Japanese pharma companies are accelerating globalization through overseas acquisitions, licensing deals, and co-development partnerships—particularly in oncology and rare diseases. Biosimilar manufacturing, leveraging Japan's precision production expertise, is also emerging as a significant growth opportunity as biologic patents expire globally.
Companies in This Sector
9
Today's Avg. Price Change
+1.39%
Simple average of constituent stock price changes vs. previous close. Not a sector index.
Updated: 2026-10-30 (JST)
Position in Japan
Japan is the world's third-largest pharmaceutical market by value, providing a stable and substantial home base. The National Health Insurance system, while exerting downward pricing pressure through biennial drug price revisions, ensures broad market access for approved therapies and a predictable revenue floor.
Latest Press Releases
02
Sep
Astellas Pharma Inc. JP3942400007
2026-09-01 Astellas Pharma Inc. “We have reached an agreement with the U.S. government to help improve access to medicines in terms of price.”
02
Sep
Kyowa Kirin Co.,Ltd. JP3256000005
2026-09-01 Kyowa Kirin Co.,Ltd. “Kyowa Kirin announces agreement with U.S. government to promote reduced medical costs in the United States.”
01
Sep
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-08-31 Sumitomo Pharma Co.,Ltd. “It was selected as one of the five constituent stocks of the ESG investment index adopted by GPIF.”
29
Aug
Otsuka Holdings Co.,Ltd. JP3188220002
2026-08-28 Otsuka Holdings Co.,Ltd. “Otsuka Holdings and Sojitz have signed a virtual PPA with a special purpose company they established – promoting carbon neutrality initiatives through the expansion of "self-generated renewable energy."”
29
Aug
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-08-28 DAIICHI SANKYO COMPANY,LIMITED “Phase 1 clinical trial of the new ADC DS1025 in patients with solid tumors has begun (252.6KB). (PDF file will open in a new window.)”
29
Aug
Shionogi & Co.,Ltd. JP3347200002
2026-08-28 Shionogi & Co.,Ltd. “Regarding the US government's procurement of cefiderocol, a drug used to treat Gram-negative bacterial infections.”
29
Aug
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-08-28 Sumitomo Pharma Co.,Ltd. “Notice Regarding the Recognition of Retirement Benefit Trust Return Gain (Extraordinary Income) in Our Individual Financial Statements (Japanese GAAP).”
28
Aug
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-08-27 DAIICHI SANKYO COMPANY,LIMITED “Phase 3 clinical trial of datopotamab deruxtecan (Dato-DXd/DS-1062) for adjuvant therapy after surgery for urothelial carcinoma has begun (244.4KB). (PDF file will open in a new window.)”
28
Aug
Astellas Pharma Inc. JP3942400007
2026-08-27 Astellas Pharma Inc. “We have been appointed as a host city partner for the One Young World 2027 Tokyo Summit.”
27
Aug
Shionogi & Co.,Ltd. JP3347200002
2026-08-26 Shionogi & Co.,Ltd. “Regarding the signing of an agreement with Susmed Co., Ltd. concerning the termination of the sales partnership agreement for an app for treating insomnia.”
27
Aug
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-08-26 Sumitomo Pharma Co.,Ltd. “Announcement regarding the selection of stocks to be included in the "JPX Prime 150 Index".”
26
Aug
Eisai Co.,Ltd. JP3160400002
2026-08-25 Eisai Co.,Ltd. “LEQEMBI IQLIK®, a subcutaneous injection formulation of the anti-Aβ antibody LEQEMBI®, has been launched in the United States as an initial treatment for early-stage Alzheimer's disease. LEQEMBI IQLIK is the world's first and only anti-amyloid therapy that offers the convenience of home administration from initial treatment to maintenance therapy.”
26
Aug
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-08-25 CHUGAI PHARMACEUTICAL CO.,LTD. “Bamikibalt has been submitted for manufacturing and marketing approval in Japan for the treatment of macular edema associated with non-infectious uveitis.”
26
Aug
Astellas Pharma Inc. JP3942400007
2026-08-25 Astellas Pharma Inc. “An international collaborative Phase III trial has been initiated for ASP2138 CLDN18.2-positive, HER2-negative, unresectable locally advanced or metastatic gastric adenocarcinoma and gastroesophageal junction adenocarcinoma.”
26
Aug
Kyowa Kirin Co.,Ltd. JP3256000005
2026-08-25 Kyowa Kirin Co.,Ltd. “The menin inhibitor ziftomenib has received orphan drug designation in Japan for acute myeloid leukemia with NPM1 gene mutations or KMT2A gene rearrangements (586KB).”
25
Aug
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-08-24 DAIICHI SANKYO COMPANY,LIMITED “Announcement regarding the establishment of a new Commercialization Unit and the selection of a Chief Commercialization Officer (CCO) (183.3KB) PDF file will open in a new window.”
22
Aug
Shionogi & Co.,Ltd. JP3347200002
2026-08-21 Shionogi & Co.,Ltd. “Regarding support for those affected by the heavy rains in Chiba Prefecture in August 2026.”
22
Aug
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-08-21 Sumitomo Pharma Co.,Ltd. “Materials from the President's press conference and press briefing (held on August 21, 2026) are posted here.”
22
Aug
Kyowa Kirin Co.,Ltd. JP3256000005
2026-08-21 Kyowa Kirin Co.,Ltd. “Notice regarding changes to the C-Suite Executive structure (381KB).”
21
Aug
Otsuka Holdings Co.,Ltd. JP3188220002
2026-08-20 Otsuka Holdings Co.,Ltd. “Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer (Link to Taiho Oncology's English page).”